ImpriMed
ImpriMed delivers personalized drug response predictions to help veterinarians choose effective treatments for canine lymphoma and leukemia. The company uses proprietary lab testing on live cancer cells combined with artificial intelligence, flow cytometry, PARR, and high-throughput screening to predict efficacy of anticancer drugs. ImpriMed operates as a SaaS platform serving veterinary oncologists and has partnered with over 250 specialists across 40 U.S. states, processing more than 21,000 canine and feline lymphoma tests. The validated platform is being extended toward human oncology to inform clinicians with data-driven treatment predictions.
ImpriMed
ImpriMed delivers personalized drug response predictions to help veterinarians choose effective treatments for canine lymphoma and leukemia. The company uses proprietary lab testing on live cancer cells combined with artificial intelligence, flow cytometry, PARR, and high-throughput screening to predict efficacy of anticancer drugs. ImpriMed operates as a SaaS platform serving veterinary oncologists and has partnered with over 250 specialists across 40 U.S. states, processing more than 21,000 canine and feline lymphoma tests. The validated platform is being extended toward human oncology to inform clinicians with data-driven treatment predictions.